- Home
- SLDP vs MNMD Comparison
SLDP vs MNMD Comparison
Compare SLDP & MNMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLDP
- MNMD
- Stock Information
- Founded
- SLDP 2011
- MNMD 2019
- Country
- SLDP United States
- MNMD United States
- Employees
- SLDP N/A
- MNMD N/A
- Industry
- SLDP Electrical Products
- MNMD Pharmaceuticals and Biotechnology
- Sector
- SLDP Energy
- MNMD Health Care
- Exchange
- SLDP Nasdaq
- MNMD Nasdaq
- Market Cap
- SLDP 446.6M
- MNMD 509.2M
- IPO Year
- SLDP N/A
- MNMD N/A
- Fundamental
- Price
- SLDP $3.34
- MNMD $9.36
- Analyst Decision
- SLDP Buy
- MNMD Strong Buy
- Analyst Count
- SLDP 2
- MNMD 7
- Target Price
- SLDP $1.50
- MNMD $24.71
- AVG Volume (30 Days)
- SLDP 13.8M
- MNMD 1.3M
- Earning Date
- SLDP 08-06-2025
- MNMD 07-31-2025
- Dividend Yield
- SLDP N/A
- MNMD N/A
- EPS Growth
- SLDP N/A
- MNMD N/A
- EPS
- SLDP N/A
- MNMD N/A
- Revenue
- SLDP $20,202,000.00
- MNMD N/A
- Revenue This Year
- SLDP $28.39
- MNMD N/A
- Revenue Next Year
- SLDP $38.07
- MNMD N/A
- P/E Ratio
- SLDP N/A
- MNMD N/A
- Revenue Growth
- SLDP 3.22
- MNMD N/A
- 52 Week Low
- SLDP $0.68
- MNMD $4.70
- 52 Week High
- SLDP $4.77
- MNMD $10.44
- Technical
- Relative Strength Index (RSI)
- SLDP 50.97
- MNMD 59.28
- Support Level
- SLDP $3.13
- MNMD $7.96
- Resistance Level
- SLDP $4.68
- MNMD $10.09
- Average True Range (ATR)
- SLDP 0.51
- MNMD 0.57
- MACD
- SLDP -0.11
- MNMD -0.09
- Stochastic Oscillator
- SLDP 20.95
- MNMD 61.40
About SLDP Solid Power Inc.
Solid Power Inc is engaged in solid-state battery technology and manufacturing processes. Its core technology is a sulfide-based solid electrolyte material, which replaces the liquid or gel electrolyte used in traditional lithium-ion battery cells. Its commercialization strategy is to manufacture and sell electrolytes to Tier 1 battery manufacturers and automotive original equipment manufacturers (OEMs) that choose to produce its battery cells.
About MNMD Mind Medicine (MindMed) Inc.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).